Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Associati... (ved a single treatment in bothlegs of ei...)

Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting

Date:6/8/2008

ved a single treatment in both legs of either placebo (12 subjects) or SB-509 (12 subjects who received 60 mg total dose, 30 mg per leg). All of the subjects completed 6-month follow-up testing. SB-509 was well tolerated and no drug-related severe adverse events were observed. Clinically relevant and statistically significant improvements were seen in neurologic examination using the Neurological Impairment Score - Lower Limbs (NIS-LL) and quantitative sensory testing (QST) which quantifies perception of vibration. In addition, there was a trend towards improvement in nerve conduction velocity (NCV), a measure of the ability of a nerve to transmit an applied electrical signal, in both sensory and motor nerves.

Specifically, improvement in neurologic evaluation by NIS-LL in SB-509-treated subjects was measured as a statistically significant, clinically relevant improvement of 1.9 point change from baseline levels compared to a 0.7 point worsening in the placebo group (a delta in NIS-LL of 2.6, p=0.043). In addition, there was a 25.3% improvement in detection of mechanical sensation compared to baseline, as measured by QST testing, in SB-509-treated patients compared to a 5.1% worsening in the placebo group (a delta in QST of 30.4%, p=0.02). The mean improvement in sensory (sural) NCV measurements 180 days post treatment was 1.2 Meters/sec with SB-509 treatment compared to -0.4 Meters/sec with placebo (a delta in NCV of 1.6 Meters/sec). The mean sum of improvement of all lower extremity motor NCV measurements 180 days post treatment was 0.8 Meters/sec with SB-509 treatment compared to -0.9 Meters/sec with placebo (a delta in NCV of 1.7 Meters/sec).

While the primary end-point of Sangamo's Phase 1b study (SB-509-401) was safety, data were also collected that were designed to measure changes in neurological health. Quantitative sensory testing (QST) using the Vibratron II is used as a method of assessing a subject's change in vibration sensitivity. Direct
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results

Post Your Comments:

Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Associati...(ved a single treatment in bothlegs of ei...),Health